In the time before ledipasvir was available, clinical trials with sofosbuvir-based regimens (such as sofosbuvir + ribavirin, or sofosbuvir + interferon + ribavirin) resulted in generally high rates of SVR12. However, there have been cases where HCV was not cured in people who used those sofosbuvir-containing regimens.
Researchers enrolled 51 people who were not cured with sofosbuvir-based regimens and retreated them with the potent combination of ledipasvir + sofosbuvir for 12 weeks.
The average profile of participants at the start of the study was as follows:
Out of 51 participants, 50 (98%) developed an SVR12.
In one participant who relapsed, technicians discovered HCV genotype 3a infection. Ledipasvir + sofosbuvir are not highly effective against this strain of HCV.
Wyles DL, Pockros PJ, Yang JC, et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract 235.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|